Prognostic and histogenetic roles of biomarker immunoprofile and gene alteration in salivary duct carcinomas
| Project/Area Number |
15K10823
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | International University of Health and Welfare |
|---|
Principal Investigator |
Tada Yuichiro 国際医療福祉大学, 医学部, 准教授 (70292430)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
長尾 俊孝 東京医科大学, 医学部, 主任教授 (90276709)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 唾液腺導管癌 / HER2 / アンドロゲン受容体 / 個別化治療 / トラスツズマブ / アンドロゲン遮断療法 / バイオマーカー / TP53遺伝子変異 / Glasgow prognostic score / ｐ53 / 下流シグナル |
|---|
| Outline of Final Research Achievements |
Salivary duct carcinoma (SDC) is an uncommon, aggressive malignant neoplasm of salivary gland. SDC can arise de novo or ex pleomorphic adenoma. We investigated the gene alterations and the immunoexpression of biomarker immunoprofile in 151 SDCs. In multivariate analysis, the cases with androgen receptor negative, CK5/6 positive and p53-extreme negative/positive and the cases harboring TP53 truncating mutations were associated with shorter progression-free survival. SDCs ex pleomorphic adenoma more commonly overexpressed EGFR, HER2, HER3 and Ki-67 than de novo SDCs, and PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma, suggesting that the mechanism of carcinogenesis of SDC varies depending on tissue development. Furthermore, a strong correlation was found between TP53 missense mutation and p53 positive, TP53 truncation mutation and p53 pole negative.
|
Report
(4 results)
Research Products
(36 results)
-
-
-
-
-
-
-
[Journal Article] A study of 12 cases of submandibular gland carcinoma2017
Author(s)
伏見千宙, 多田雄一郎, 増淵達夫, 松木崇, 菅野千敬, 岡田拓郎, 佐々木剛史, 丹羽一友, 町田智正, 三浦弘規, 黒坂正生, 鎌田信悦, 玉井誠一
-
Journal Title
JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
Volume: 27
Issue: 1
Pages: 67-72
DOI
NAID
ISSN
1349-581X, 1884-474X
Related Report
Peer Reviewed
-
[Journal Article] Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.2017
Author(s)
Kawakita D, Tada Y, Imanishi Y, Beppu S, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Shimizu A, Sato Y, Fushimi C, Takase S, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Shimura T, Hanazawa T, Murakami S, Nagao T.
-
Journal Title
Oncotarget
Volume: 8(1)
Issue: 1
Pages: 1083-1091
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients2016
Author(s)
Otsuka K, Imanishi Y, Tada Y, Kawakita D, Kano S, Tsukahara K, Shimizu A, Ozawa H, Okami K, Sakai A, Sato Y, Ueki Y, Sato Y, Hanazawa T, Chazono H, Ogawa K, Nagao T.Ann Surg Oncol.
-
Journal Title
Ann Surg Oncol.
Volume: 23
Issue: 6
Pages: 2038-2045
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
[Presentation] 唾液腺導管癌ではFOXA1の発現が予後予測因子となる2016
Author(s)
平井秀明,多田雄一郎,川北大介,志村智隆,塚原清彰,加納里志,清水顕,今西順久,小澤宏之,大上研二,佐藤雄一郎,長尾俊孝
Organizer
第61回日本唾液腺学会
Place of Presentation
東京
Year and Date
2016-12-03
Related Report
-
-
-
[Presentation] 唾液腺導管癌における免疫組織化学的発現解析 －多施設共同による152症例の検討－2016
Author(s)
加納里志,高瀬聡一郎,多田雄一郎,川北大介,塚原清彰,清水顕,今西順久,小澤宏之,大上研二,佐藤雄一郎,佐藤由紀子,志村智隆,花澤豊行,長村義之,長尾俊孝
Organizer
第54回日本癌治療学会学術集会
Place of Presentation
横浜
Year and Date
2016-10-20
Related Report
-
-
[Presentation] TRASTUZUMAB AND DOCETAXEL FOR HER2-POSITIVE UNRESECTABLE SALIVARY GLAND CARCINOMA: UPDATED RESULTS OF A PHASE II TRIAL2016
Author(s)
Hideaki Takahashi, MD, PhD1, Tatsuo Masubuchi1, Chihiro Fushimi1, Takashi Matsuki1, Toru Inomata1, Takuro Okada1, Chihiro Kanno1, Yoshiyuki Osamura2, Toshitaka Nagao3, Takashi Saotome4, Shuhei Yamada5, Hiroya Ojiri6, Daisuke Sano7, Nobuhiko Oridate7, Jeffrey N Myers8, Kouki Miura1, Yuichiro Tada1
Organizer
AHNS 9th International Conference on Head and Neck Cancer
Place of Presentation
Seattle
Year and Date
2016-07-16
Related Report
Int'l Joint Research
-
[Presentation] 根治手術を施行した唾液腺導管癌における術前採血マーカーの予後への影響2016
Author(s)
別府慎太郎,多田雄一郎,川北大介,塚原清彰,加納里志,清水顕,今西順久,小澤宏之,大上研二,佐藤雄一郎,花澤豊行,長尾俊孝
Organizer
第40回日本頭頸部癌学会
Place of Presentation
大宮
Year and Date
2016-06-09
Related Report
-
[Presentation] 唾液腺導管癌における標的遺伝子変異と免疫組織化学的発現の検討：その臨床病理学的因子との関連2016
Author(s)
志村智隆,多田雄一郎,川北大介,塚原清彰,加納里志,清水顕,高瀬聡一郎,今西順久,小澤宏之,大上研二,佐藤雄一郎,長尾俊孝
Organizer
第40回日本頭頸部癌学会
Place of Presentation
大宮
Year and Date
2016-06-09
Related Report
-
-
-
-
-
-
[Presentation] Androgen Deprivation Therapy for Androgen Receptor-Positive Unresectable Salivary Gland Carcinoma2015
Author(s)
Hideaki Takahashi, Tatsuo Masubuchi, Chiro Fushimi, Takashi Matshuki, Toshitaka Nagao, Takashi Saotome, Shuhei Yamada, Hiroya Ojiri, Nobuhiko Oridate, Kouki Miura, Yuichiro Tada
Organizer
The Joint Meeting of 4th Congress of Asian Society of Head and Neck Oncology & 39th Annual Meeting of Japan society for Head and Neck Cancer
Place of Presentation
神戸国際会議場（兵庫県神戸市）
Year and Date
2015-06-03
Related Report
Int'l Joint Research
-
[Presentation] Trastuzumab Combined with Docetaxel for HER2-positive Unresectable Salivary Gland Carcinoma2015
Author(s)
Hideaki Takahashi, Tatsuo Masubuchi, Chiro Fushimi, Takashi Matshuki, Toshitaka Nagao, Takashi Saotome, Shuhei Yamada, Hiroya Ojiri, Nobuhiko Oridate, Kouki Miura, Yuichiro Tada
Organizer
The Joint Meeting of 4th Congress of Asian Society of Head and Neck Oncology & 39th Annual Meeting of Japan society for Head and Neck Cancer
Place of Presentation
神戸国際会議場（兵庫県神戸市）
Year and Date
2015-06-03
Related Report
Int'l Joint Research
-
-
-
